FDA Grants Fast Track to BeyondSpring's Plinabulin Plus Docetaxel in Post-ICI NSCLC
核心洞察
The FDA granted Fast Track designation to Plinabulin plus docetaxel for advanced or metastatic non-squamous NSCLC that has progressed after checkpoint inhibitor therapy and chemotherapy.
The designation supports DUBLIN-4, a randomized global Phase 3 trial planning to enroll 442 patients with overall survival as the primary endpoint.
BeyondSpring entered a definitive agreement with Biolin (搜索) to fund the China portion of DUBLIN-4, expected to supply about half of global enrollment.
The FDA has granted Fast Track designation to Plinabulin plus docetaxel for the treatment of advanced or metastatic non-squamous non-small cell lung cancer (搜索) (NSCLC) following progression on immune checkpoint inhibitor (ICI) therapy and chemotherapy, BeyondSpring announced.
Fast Track designation is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical needs. It provides opportunities for more frequent interactions with the FDA on the development program and may allow rolling review of a future regulatory application. Plinabulin may also be eligible for Priority Review if applicable criteria are met.
"We believe the FDA Fast Track designation, an FDA-aligned global Phase 3 strategy, and funding to support China-generated clinical data would meaningfully strengthen our ability to advance Plinabulin and DUBLIN-4 toward the trial's next major clinical milestone, the prespecified interim analysis at 221 PFS events," said Min Qiu, CEO of BeyondSpring.
DUBLIN-4 Design and Endpoints
DUBLIN-4 is a randomized global Phase 3 trial evaluating Plinabulin plus docetaxel versus docetaxel alone in patients with advanced non-squamous NSCLC without actionable genomic alterations following progression on ICI and chemotherapy. Approximately 442 patients are planned to be randomized 1:1. Overall survival is the primary endpoint, with progression-free survival (PFS) and objective response rate (ORR) as secondary endpoints. The trial includes a prespecified interim analysis at 221 PFS events.
Approximately half of the planned trial population is expected to be enrolled at participating sites in China under a strategic arrangement, with the remainder enrolled through the broader global program, including in the United States and other regions. BeyondSpring intends for data generated across participating regions to form part of an integrated global clinical dataset supporting its registration strategy for Plinabulin.
Strategic Transaction Funds the China Cohort
BeyondSpring has entered into a definitive agreement with Dalian Wanchunbulin Pharmaceuticals Ltd. (搜索), its Chinese subsidiary ("Bulin"), and Biolin (搜索), under which BeyondSpring will sell BeyondSpring Ltd., its wholly owned subsidiary that indirectly holds the majority equity interest in Bulin, to Biolin.
Under the arrangement, Biolin (搜索) will support funding of clinical development activities conducted by Bulin at participating sites in China, and BeyondSpring will receive access to clinical data generated from the China portion of DUBLIN-4. Biolin's obligation to support funding of the China portion of the trial, and to cause Bulin to conduct and use commercially reasonable efforts to complete the trial and perform certain related activities, constitutes the non-cash consideration for the sale of BeyondSpring Ltd.
Following the transaction, BeyondSpring will retain global rights to Plinabulin outside Greater China. The arrangement is expected to substantially reduce BeyondSpring's cash requirements associated with DUBLIN-4, while China's large eligible NSCLC patient population is expected to support efficient enrollment.
Rationale From DUBLIN-3 and Study 303
Plinabulin is a late-stage, first-in-class investigational GEF-H1 (搜索) agonist with a differentiated mechanism of action that includes dendritic cell maturation, anti-angiogenic activity and mitigation of chemotherapy-induced neutropenia. More than 700 cancer patients have been treated with Plinabulin across multiple clinical programs in various cancer types.
The post-ICI setting remains difficult to treat. Twelve Phase 3 trials evaluating different treatment approaches against docetaxel, including four involving antibody-drug conjugates (ADCs), have failed to demonstrate an overall survival benefit over docetaxel.
In the Phase 3 DUBLIN-3 trial, published in The Lancet Respiratory Medicine in 2024, Plinabulin combined with docetaxel demonstrated a statistically significant improvement in OS in second- and third-line EGFR wild-type NSCLC versus docetaxel alone (n=559), with superior OS benefit in non-squamous patients (n=332, OS HR 0.72, p=0.0078). The combination also showed statistically significant improvements versus docetaxel alone, including doubling of 2-year and 3-year survival rates and improvements in PFS and ORR, while significantly reducing grade 4 neutropenia (p<0.0001).
A post hoc analysis of the DUBLIN-3 post-ICI subgroup showed a median OS of 15.8 months with Plinabulin plus docetaxel versus 11.7 months with docetaxel alone (HR 0.55), with ORR of 18.2% versus 8.0%, respectively. These findings support the clinical rationale for Plinabulin's dendritic cell maturation mechanism and its further evaluation in DUBLIN-4.
Prospective data from the Phase 2 Study 303 (n=47), presented at ASCO 2026, further supported this rationale. In patients with NSCLC whose disease had progressed following PD-1 (搜索) inhibitor treatment, the combination of Plinabulin, docetaxel and a PD-1 inhibitor demonstrated encouraging anticancer activity. With a median follow-up of 28.8 months, the Plinabulin combination showed a median PFS of 7.0 months, a disease control rate of 79.5%, and a confirmed ORR of 18.2%, with a 2-year OS rate of 58%, nearly double the historical rate reported with docetaxel in a similar patient population.
BeyondSpring is a clinical-stage biopharmaceutical company developing therapies for cancers with high unmet needs. Plinabulin has been studied in more than 700 cancer patients and is in late-stage development across multiple cancer indications. Its mechanism as a GEF-H1 (搜索) agonist with dendritic cell maturation benefit supports both anticancer activity and immune modulation, offering an approach to resensitizing tumors that have progressed on checkpoint inhibitors. The company states that Plinabulin has the potential to synergize with chemotherapy, ADCs, radiation and checkpoint inhibitors.